Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06432465 · ClinicalTrials.gov registry record · NA

tDCS to Decrease Opioid Relapse (UH3)

A NA study of Opioid Use Disorder, sponsored by Butler Hospital.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06432465 is a NA study of Opioid Use Disorder that is actively recruiting participants, run by Butler Hospital. The registered enrollment target is 100 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06432465, a NA study of Opioid Use Disorder, is actively recruiting participants, sponsored by Butler Hospital.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.

Conditions Studied

Interventions

  • DEVICE sham tDCS
  • DEVICE active tDCS

Study Locations (1)

Rhode Island

  • Butler Hospital - Providence

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-04-17
Est. Completion 2026-12-31
Phase NA

Sponsor

Butler Hospital

103 total trials

What the Registry Record Tells You About NCT06432465

The ClinicalTrials.gov registry entry for NCT06432465 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Butler Hospital, which has 103 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which sham tDCS is the first listed.

NCT06432465 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT06432465 about?

NCT06432465 is a clinical study titled "tDCS to Decrease Opioid Relapse (UH3)". Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided va...

What is the current status of trial NCT06432465?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-04-17. Estimated completion is 2026-12-31.

What conditions does trial NCT06432465 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT06432465?

The interventions under investigation include: sham tDCS (DEVICE), active tDCS (DEVICE).

Who is sponsoring clinical trial NCT06432465?

This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06432465 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.